Combining Immune Therapy, Pembrolizumab, and Chemotherapy as First Line Treatment
for Lung Cancer
Is treatment with one chemotherapy medication combined with immune therapy (pembrolizumab)
tolerable and effective for patients with lung cancer?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
The purpose of this study is to understand if treatment with one chemotherapy medication
combined with immune therapy (pembrolizumab) is tolerable and effective for patients
with lung cancer and performance status of 2 (PS2), which means you have limitations
in carrying out certain activities or spend up to half of your day resting.
Study Reference #: ULUN19148
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Amy Jasek
Phone: (585) 273-1912
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search